If the estrogen receptor (ER) was used as a biomarker for distinguishing BC in patients, expression of miR-155 at the Youden cutoff of 0.3397 could identify the healthy group from ER− and ER+ in BC with a sensitivity of 80.75% and specificity of 80.64% (Table 9). This evidence concerns the gene ESR1 and breast cancer.